# Insulin medicines: Use case

Source page: https://www.materialinsights.org/products/p_insulin_medicines/prod-use/

#### Use cases

Each use, its share of demand and volume, how critical the product is to it and why, and the price paid

| Use case | Volume | Unit | Criticality | Reason | Year | Source |
|---|---|---|---|---|---|---|
| People with type 1 diabetes (world, WHO 2021) | 9 million | people | Essential | WHO: people with type 1 diabetes need insulin injections for survival. | 2021 | ^[1]^[2] |
| People with type 2 diabetes for whom insulin is essential (world, WHO 2021, more than) | 60 million | people | Essential | WHO says insulin is essential for them; one in two of those who need it do not get it. | 2021 | ^[1] |
| People on insulin therapy in India (type 1 and type 2, as reported) | 6 million | people | Essential | These patients are on insulin therapy; Novo Nordisk expects 9 million users in the near future, the article says. | 2026 | ^[10] |

as of 2026-11-13

#### Industries that buy it

The industries and kinds of firm that buy it, for which use case, and how critical it is to them
 Used by

- [Healthcare services](https://www.materialinsights.org/industries/healthcare/) Treatment of diabetes · criticality essential Clinics, hospitals and pharmacies supply insulin to patients, who inject it themselves; no share found.

as of 2026-11-13

#### How it is used

Lifetime, use per year and utilisation, by variant

| Measure | Value | Unit | Place | Year | Source |
|---|---|---|---|---|---|
| Pens used per patient in a year, once-daily basal insulin (modelled by authors from Novo Nordisk and Putnam) | 22 | pens per year | France | 2024 | ^[14] |
| Pens used per patient in a year, once-weekly basal insulin (modelled by authors from Novo Nordisk and Putnam) | 5 | pens per year | France | 2024 | ^[14] |
| People on insulin therapy (as reported in the press, roughly) | 6 | million people | India | 2026 | ^[10] |
| People living with diabetes, all types and treatments | 830 | million people | World | 2022 | ^[2] |

as of 2026-11-13

#### Prices

Unit prices by market or use, with year and source

| Market | Value | Unit | Year | Source |
|---|---|---|---|---|
| US manufacturer gross price per 100 IU as a multiple of the price in 33 OECD comparison countries combined | 9.71 | times | 2022 | ^[9] |
| US net price per 100 IU after estimated gross-to-net discounts, as a multiple of the price in the comparison countries combined | 2.33 | times | 2022 | ^[9] |
| Analogue insulins against human insulins, at least (WHO; in some countries three times) | 1.5 | times the price | 2021 | ^[1] |
| Biosimilar insulins against the originator product, could be cheaper by more than | 25 | % | 2021 | ^[1] |
| Awiqli (once-weekly insulin), 1 ml pen, India (as reported by BioSpectrum India; not confirmed from an official price list) | 2611 | INR | 2026 | ^[10] |
| Awiqli, 3 ml pen, India (as reported by BioSpectrum India; not confirmed from an official price list) | 7833 | INR | 2026 | ^[10] |
| Once-weekly 70-unit dose of Awiqli, India, against Rs 345 to Rs 453 for 70 units of daily basal insulin (the company's own comparison, as reported) | 261 | INR | 2026 | ^[10] |

as of 2026-11-13

#### Sources

1. [New WHO report maps barriers to insulin availability and suggests actions to promote universal access](https://www.who.int/news/item/12-11-2021-new-who-report-maps-barriers-to-insulin-availability-and-suggests-actions-to-promote-universal-access) World Health Organization, 2021, news item of 12 November 2021
2. [Diabetes (fact sheet)](https://www.who.int/News-Room/Fact-Sheets/Detail/Diabetes) World Health Organization, 2026, fact sheet dated 11 November 2026
3. [Comparing Insulin Prices in the United States to Other Countries: Updated Results Using 2022 Data](https://www.rand.org/pubs/periodicals/health-quarterly/issues/v11/n3/03.html) RAND Health Quarterly (Andrew W. Mulcahy and Daniel Schwam), 11(3):3, 2024, abstract and summary
4. [India 2030: Who Supplies the Next 10 Million?](https://www.biospectrumindia.com/features/18/28731/india-2030-who-supplies-the-next-10-million.html) BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
5. [Environmental Impact of Switching from Daily to Weekly Basal Insulin Administration in France](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4014/145501) ISPOR Europe 2024 abstract EE212 (Bellier L, Antier C, Soggiu M, Virely N, Laporte L, Sivignon M, Kind B; affiliations Putnam, Paris, and Novo Nordisk, Paris), Value in Health 27(12) S2, 2024

## Other sections

- [Summary](https://www.materialinsights.org/products/p_insulin_medicines/index.md)
- [Working](https://www.materialinsights.org/products/p_insulin_medicines/prod-working/index.md)
- [Bill of materials](https://www.materialinsights.org/products/p_insulin_medicines/prod-bom/index.md)
- [Supply chain](https://www.materialinsights.org/products/p_insulin_medicines/prod-supply/index.md)
- [Footprint](https://www.materialinsights.org/products/p_insulin_medicines/prod-footprint/index.md)
- [Evolution](https://www.materialinsights.org/products/p_insulin_medicines/prod-evolution/index.md)
- [Interventions](https://www.materialinsights.org/products/p_insulin_medicines/prod-interventions/index.md)
